CD44 is a cell-surface glycoprotein involved in many cellular functions including lymphocyte activation, recirculation and homing, hematopoiesis and tumor metastasis, suggesting that CD44 may play an important role in breast cancer development. In this study, we examined whether CD44 exon 2 polymorphisms are associated with increased susceptibility to breast cancer. Direct nucleotide sequencing analysis showed that multiple single nucleotide polymorphisms were present in the CD44 exon 2 coding region in female patients with breast cancer. There was no significant difference in the frequency of any one single nucleotide polymorphism in the CD44 exon 2 coding region between patients with breast cancer and normal donors. However, CD44 polymorphisms in the CD44 exon 2 coding region were identified in approximately 40% of patients with breast cancer, which was significantly higher than in normal donors (odds ratio, 9.34; 95% confidence interval = 2.58-33.82; P < 0.0001). The Wilcoxon-Mann-Whitney test analysis showed that the patients with the CD44 polymorphisms in CD44 exon 2 coding sequence had breast cancer at earlier ages, 49 ± 3 versus 62 ± 2 years (P < 0.0005), and larger tumor burdens (4.9 ± 1.22 vs.
Introduction
Breast cancer has been shown to cause significant cancerrelated deaths among women in the USA and globally. Genetic factors play a pivotal role in susceptibility to breast cancer. Women with a family history of breast cancer, especially a first-degree relative, such as mother, sister, or daughter, have an increased risk of developing breast cancer (Loman et al., 2001) . The risk is higher if more than one first-degree relative has developed breast cancer and this increases further, the younger the relative was at the time of diagnosis (Collaborative Group on Hormonal Factors in Breast Cancer, 2001) . Thus, genetic makeup may be an important determinant of breast cancer risk. A number of breast cancer susceptibility genes have been characterized, notably BRCA1 and BRCA2, which are responsible for approximately 15% of breast cancer cases due to inherited mutations (Peto et al., 1999; Anglian Breast Cancer Study Group, 2000) . In addition, human epidermal growth factor receptor 2 polymorphism, glutathione S-transferase O1 polymorphisms and polymorphic CAG repeats in the androgen receptor gene may confer an increased risk of breast cancer in women (Pinto et al., 2004; Olsen et al., 2008; Wu et al., 2008) . The current estimates are that all the known breast cancer susceptibility genes account for less than 25% of the familial aggregation of breast cancer (Thompson and Easton, 2004) . This points to the possibility that the majority of the familial clustering of breast cancer cannot be explained and thus further studies are needed to identify other breast cancer susceptibility genes. The identification of new genes could make a major impact in risk prediction.
Genome-wide association studies provide an effective approach to identify the functional gene variations that increase or decrease the risk of cancer and thus give us new insights into risk prediction as well as preventive and therapeutic interventions. Studies of the 'dark matter' in the human genome that are not captured by the single nucleotide polymorphism (SNP)-based genome-wide association studies such as structural and rare gene variants, micro-RNAs, and epigenetics are needed to fully understand the inherited component of cancer. Thus, in this study, a direct nucleotide sequencing strategy was used to perform a fine analysis of CD44 gene polymorphisms in the CD44 exon 2 coding region in female patients with breast cancer.
CD44 is a cell surface transmembrane glycoprotein, encoded by a single gene. The human CD44 gene is located at the short arm of chromosome 11 and consists of at least 20 exons spanning approximately 50 kb of DNA. The gene is composed of two groups of exons. One group, comprising exons 1-5 and 16-20, are expressed together as the standard form. The 10 variable exons (exons 6-15) can be alternatively spliced and included within the standard exons at an insertion site between exons 5 and 16. CD44 is expressed in a variety of cells including hematopoietic, epithelial, endothelial, and those of mesodermal origin (Bourguignon et al., 1998; Nebe et al., 2006) . CD44 plays a role in tumor metastasis (Marhaba and Zoller, 2004; Hill et al., 2006) . CD44s (the standard form) is known to be important in T-cell signaling and a variety of immune cell functions. In addition, CD44s plays a role in T-cell and B-cell adhesion, cell aggregation, proliferation, and cell migration (Bourguignon et al., 1998) . CD44s is also an important cytotoxic triggering molecule on cytotoxic T lymphocytes, double-negative T cells and natural killer cells in mice (Rafi-Janajreh et al., 1998) . CD44 has also been shown to interact with hyaluronan in regulation of breast cancer cell proliferation, migration, and invasion, as well as tumor-associated angiogenesis, which correlates with patient survival (Gotte and Yip, 2006; Nebe et al., 2006) . We hypothesize that CD44 exon 2 polymorphisms may play an important role in breast cancer development.
The role of CD44 polymorphisms in breast cancer development has not been fully understood. Our earlier studies indicated that a unique SNP (designated as CD44 Ex2 + 14 A > G) in the CD44 intron 1 region was identified in 84% of patients with breast cancer, which was significantly higher than in normal donors (Zhou et al., 2010) . Moreover, the patients with breast cancer with homozygous unique SNP in the CD44 intron 1 had breast cancer at earlier ages, larger tumor burden, more regional lymph node metastases at the time of diagnosis, and higher cancer recurrence rate (Zhou et al., 2010) . In this study, we examined CD44 polymorphisms in the CD44 exon 2 coding region, an important site for CD44 ligand binding (Telen et al., 1996) , in patients with breast cancer. The results showed that multiple SNPs in the CD44 exon 2 coding region were present in approximately 40% of patients with breast cancer, which was significantly higher than in normal donors. Furthermore, the patients with breast cancer having the CD44 polymorphisms in the CD44 exon 2 coding sequence had breast cancer at an earlier age and significantly larger tumor burden when the patients were diagnosed with breast cancer. The results suggest that CD44 polymorphisms are associated with breast cancer. CD44 polymorphism analysis may be effectively used in evaluation of cancer risk, prediction, prevention, diagnosis, and genetic studies of breast cancer.
Materials and methods

Patient samples
All patients with breast cancer in this study signed an institutional review board-approved consent form. The blood samples, breast cancer specimens, and adjacent normal breast tissues deposited in the Tissue Bank at South Carolina Cancer Center (Columbia, South Carolina, USA) from 260 patients with breast cancer during 2001 and 2008 were used in this research. Among patients with breast cancer, 118 were Caucasian American female, 115 African-American female, and 27 unknown ethnic female. The patients had breast cancers from stage I to stage IIIC. The patients were between the ages of 23 and 90 years, and had an average age of 55 years at the time of diagnosis with breast cancer.
Normal donors
All normal female donors signed an institutional review board-approved consent form and were recruited in South Carolina Women's Care Study (Columbia, South Carolina, USA) in which they donated blood samples for our research. Among normal donors, 96 were Caucasian American female and 96 African-American female. In addition, genomic DNA samples from 40 healthy Caucasian American female normal donors provided by BioChain Institute, Inc., (Hayward, California, USA) were also used as normal controls.
Genomic DNA isolation
The genomic DNA was isolated from peripheral blood samples derived from female normal donors and patients with breast cancer using the AGENCOURT GENFIND v2 Blood and Serum Genomic DNA Isolation kit (Agencourt, Beverly, Massachusetts, USA) according to the manufacturer's manual. The DNA concentration of genomic DNA samples was determined by spectrophotometer and the quality of genomic DNA samples was analyzed by agarose gel electrophoresis.
Analysis of CD44 polymorphisms
A direct DNA sequencing method was used to determine the polymorphisms in the CD44 exon 2 region including the CD44 exon 2 sequence and the boundary sequences between exon 2 and upstream intron, and between exon 2 and downstream intron. In brief, 5 ng of genomic DNA from each sample was added into 50 ml of PCR reaction mixture. M13R-tagged forward primer (5 0 -CCGGCCT TATTTGACTTTTTAAGGAGTCTG-3 0 ) and M13Ftagged reverse primer (5 0 -CTCCAGTTGTCATACAGG TTGCAGATTGAC-3 0 ) were used to amplify the CD44 exon 2 region from genomic DNA samples by PCR using high fidelity DNA polymerase (Invitrogen, Carlsbad, California, USA). The PCR products were sent out to MCLAB (South San Francisco, California, USA) for clean up and direct sequencing using primers M13R and M13F. At the same time, the PCR products were cloned into pCR2.1 TOPO vector (Invitrogen), transformed into One Short TOP10F' cells (Invitrogen), and sent out to MCLAB (South San Francisco) for colony sequencing. After cloning and transformation, plasmid DNA samples were also prepared from a certain number of samples (including 60 patient samples with breast cancer and 40 normal donors) using QIAprep Spin Miniprep kit (Qiagen, Valencia, California, USA), and sent out to SeqWright (Houston, Texas, USA) for sequencing confirmation. Sequencing analysis, using Basic Local Alignment Search Tool searching for SNPs, was carried out to determine CD44 polymorphisms in the CD44 exon 2 region.
Statistical analysis
Odds Ratio Generator Version 1.0.0 (Devilly G.J., 2005, Centre for Neuropsychology, Swinburne University, Melbourne, Australia) was used to calculate odds ratios (OR) and 95% confidence intervals to analyze the statistical differences of CD44 polymorphisms between two groups. The OR ranges from 0 to positive infinity, with 1.0 indicating that the condition or event under study is equally likely in both groups. An OR greater than 1 indicates that the condition or event is more likely in the second group. Two-sample proportion test was used to confirm the statistical differences. Proportion trend test was used to correct the statistics for multiple hypothesis testing. The Fisher exact test and the Wilcoxon-Mann-Whitney test were used to determine the association between CD44 polymorphism and breast cancer development, and the association was considered significant at a P value of less than 0.05.
Hardy-Weinberg equilibrium test of SNP was performed using Michael H. Court's (2005 Court's ( -2008 online calculator (http://www.tufts.edu/~mcourt01/Documents/ Court%20lab%20-% 20HW%20calculator.xls). Tests in patients with breast cancer (P = 0.4962) and normal female donors (P = 0.7222) did not show any significant deviation from Hardy-Weinberg equilibrium for any of the SNPs.
The Kaplan-Meier approach was used to generate both probability curves and cumulative risk curves for breast cancer between the female patients with breast cancer who did not have CD44 polymorphisms in CD44 exon 2 coding region and those who had CD44 polymorphisms in CD44 exon 2 coding region, which was confirmed by the 'survival' package in R Statistical Software (http://www. r-project.org) using command 'survfit'. The Gehan rank test was used to determine the statistical differences and the difference was considered significant at a P value of less than 0.05.
Results
Identification of CD44 polymorphisms in CD44 exon 2 coding region
The human CD44 gene has been mapped to the chromosomal locus 11p13 and is composed of two groups of exons. One group, comprising exons 1-5 and 16-20, are spliced together to form a transcript that encodes the ubiquitously expressed standard isoform (abbreviated to CD44s). The 10 variable exons 6-15 (also known as v1-10) can be alternatively spliced and included within the standard exons at an insertion site between exons 5 and 16 (Goodison et al., 1999) . CD44 exon 2 is critical for CD44 binding to its ligand, hyaluronan (Peach et al., 1993) . Therefore, at first, we were interested in analyzing the polymorphisms in the CD44 exon 2 region and their role in breast cancer development. The direct nucleotide sequencing analysis indicated that CD44 polymorphism in the CD44 coding region was present in patients with breast cancer (Fig. 1) . Thus, in addition to the unique CD44 Ex2 + 14 A > G polymorphism in the upstream intron region (intron1) of CD44 exon 2 (Zhou et al., 2010) , one or more additional polymorphisms in the CD44 exon 2 coding sequence were also present in patients with breast cancer.
Comparison of CD44 polymorphisms in CD44 exon 2 coding region between female patients with breast cancer and normal donors
The direct nucleotide sequencing analysis showed 23 additional polymorphic loci within the CD44 exon 2 coding region in patients with breast cancer (Fig. 2a ). We observed 10 synonymous changes and 13 nonsynonymous changes, one of which introduced a stop codon at amino acid position 67. The nonsynonymous changes all resulted in nonconservative amino acid substitutions, Representative chromatogram of a single nucleotide polymorphism in CD44 exon 2 coding region identified in female patients with breast cancer. NT_009237 was the access number of Homo sapiens chromosome 11 genomic contig containing CD44 gene sequence in GenBank. The CD44 polymorphic change from C to A was highlighted in green at mRNA nucleotide position 615 in CD44 exon 2 coding sequence, leading to amino acid substitution of proline by threonine at amino acid position 61. A, T, G, and C nucleotides were denoted by green, red, black, and blue curves, respectively.
suggesting that CD44 polymorphisms in the CD44 exon 2 coding region may affect CD44 expression and functions.
The frequency of any single SNP in the CD44 exon 2 coding region in patients with breast cancer was very low (Table 1) . On the basis of the frequency of SNPs in CD44 exon 2 coding region identified in patients with breast cancer, four types of SNPs, SNP-A, SNP-B, SNP-C, and SNP-D at a frequency of 0.38, 0.77, 1.54, and 2.69% in patients with breast cancer, respectively, were distinguished. There was no significant difference in frequency of any single SNPs in the CD44 exon 2 coding region between patients with breast cancer and normal donors (Fig. 2b) . However, CD44 polymorphisms in the CD44 exon 2 coding region were identified in approximately 40% of all patients with breast cancer under investigation, which was significantly higher than in normal donors (OR, 9.34 ; 95% confidence interval = 2.58-33.82; P < 0.0001; Fig. 3 ). Furthermore, when compared with healthy normal female donors, both Caucasian and African-American patients with breast cancer had a significantly increased frequency of CD44 polymorphisms in the CD44 exon 2 coding region. There was also a significant difference of CD44 polymorphism frequencies between Caucasian and African-American patients (P < 0.001; Fig. 3 ). The results indicated that CD44 polymorphisms in the CD44 exon 2 coding sequence may also play a role in breast cancer development. Identification of single nucleotide polymorphisms (SNPs) in CD44 exon 2 coding region in female patients with breast cancer. (a) CD44 polymorphisms in CD44 exon 2 coding region. Multiple different CD44 polymorphic changes were identified in female patients with breast cancer. Synonymous changes were noted bold in red, nonsynonymous missense mutations were underlined in red, and the stop codon mutation was underlined and italicized in green.
(b) Comparison of CD44 polymorphisms in CD44 exon 2 coding region between female patients with breast cancer and normal donors. On the basis of the frequency of SNPs in CD44 exon 2 coding region identified in patients with breast cancer, four types of SNPs, SNP-A, SNP-B, SNP-C, and SNP-D (from the lowest frequency through the highest frequency), were distinguished (Table 1) . The Fisher exact test was used to determine the statistical difference of SNP frequencies between two groups. No significant difference of any SNPs in CD44 exon 2 coding region between patients with breast cancer and normal donors were found. 
Relationship between CD44 polymorphisms and breast cancer development
Considering that female patients with breast cancer had significantly increased frequencies of CD44 polymorphisms in the CD44 exon 2 region than normal female donors (Fig. 3) , we were interested in understanding the clinical significance of CD44 polymorphisms in breast cancer development. As not all of patients with breast cancer exhibited CD44 polymorphisms in the CD44 exon 2 coding region (Figs 2 and 3) , we divided the patients with breast cancer into two groups: (a) group I patients are those that did not have the CD44 polymorphisms in the CD44 exon 2 coding region, and (b) group II patients are those that had one or more CD44 polymorphisms in the CD44 exon 2 coding sequence. The Wilcoxon-Mann-Whitney test showed that the group II female patients with breast cancer having the CD44 polymorphisms in the CD44 exon 2 coding sequence had breast cancer at an earlier age and larger tumor sizes when they were diagnosed with breast cancer; these differences were statistically significant (Fig. 4) . Interestingly, as compared with Caucasian American women, African-American women having the CD44 polymorphisms in CD44 exon 2 coding sequence were diagnosed with breast cancer at a relatively younger age (Fig. 4e) . These data indicated that CD44 polymorphisms in the CD44 exon 2 coding region may play an important role in breast cancer development.
Estimation of breast cancer probability and risk
Statistical analysis showed that the patients having the CD44 polymorphisms in CD44 exon 2 coding sequence had significantly higher probability and higher cumulative risk for breast cancer (Fig. 5) . For instance, a patient with a CD44 polymorphism in CD44 exon 2 coding sequence had 0.23 (1 -0.77 = 0.23, or 23%) probability for breast cancer at the age of 40 years and 0.73 (1 -0.27 = 0.73 or I patients  Group II patients   Group I patients  Group II patients   Group I patients  Group II patients   Group I patients  Group II patients   Group I patients  Group II patients   Group I patients  Group II 
Association of CD44 polymorphisms with patient age and tumor size at breast cancer diagnosis. The ages were compared at breast cancer diagnosis between group I and group II patients from all (a), Caucasian American (c), and African-American (e) female patients with breast cancer and the tumor sizes at breast cancer diagnosis between group I and group II patients from all (b), Caucasian American (d), and African-American (f) female patients with breast cancer. Group I patients are those female patients with breast cancer who did not have the CD44 polymorphisms whereas group II patients are those with CD44 polymorphisms in CD44 exon 2 coding sequence as shown in Fig. 2a . The Wilcoxon-Mann-Whitney test was used to determine the statistical differences in the age of patients and tumor sizes between two groups. 73%) probability at the age of 60 years, whereas the patients without any CD44 polymorphisms in CD44 exon 2 coding sequence had 0.03 probability for breast cancer at the age of 40 years and 0.53 probability at the age of 60 years (Fig. 5) . Thus, based on the breast cancer probability curve and cumulative risk curve, we may establish a prediction model for breast cancer risk.
Discussion
CD44 is a multifunctional transmembrane protein involved in cell proliferation, angiogenesis, invasion, and metastasis (So et al., 2011) . CD44 and its interaction with hyaluronan may regulate breast cancer cell proliferation, migration, and invasion, as well as tumor-associated angiogenesis, and are correlated with patient survival (Nebe et al., 2006; Gotte and Yip, 2006) . Thus, CD44 may play a role in breast cancer development. Our earlier studies showed that the unique SNP (CD44 Ex2 + 14 A > G) in CD44 intron 1 is associated with breast cancer development (Zhou et al., 2010) . In this study, we further examined the gene polymorphisms in CD44 exon 2 coding sequence in patients with breast cancer. Our results showed that CD44 gene polymorphisms were present in the CD44 exon 2 coding region in patients with breast cancer (Figs 1 and 2a ). As compared with normal donors, the frequencies of SNPs in the CD44 exon 2 coding region in patients with breast cancer are not higher ( Fig. 2b and Table 1 ); however, the combined frequency of all SNPs in patients with breast cancer was significantly higher than that in normal donors (Fig. 3 ), suggesting that CD44 polymorphisms in CD44 exon 2 coding sequence play a role in breast cancer development. A recent report also indicated that germline polymorphisms in the CD44 gene are associated with clinical outcome in localized gastric adenocarcinoma (Winder et al., 2010) and sarcoma incidence and survival (Vazquez et al., 2010) . Thus, CD44 gene variations may be a risk factor for cancers.
Multiple SNPs in the CD44 exon 2 coding region were identified in patients with breast cancer (Fig. 2) . Some of these polymorphic changes were nonsense mutations; however, it is possible that these nonsense mutations may somehow influence RNA stability and thus decrease CD44 expression. Some of them were sense mutations, resulting in the mutated CD44 proteins, and one of them was an Amber stop codon mutation, resulting in the truncated CD44 proteins. Therefore, the CD44 polymorphisms in CD44 exon 2 coding region may affect CD44 expression and functions. Further studies will be needed to determine the relationship of CD44 polymorphisms with CD44 expression and functions. Nonetheless, it is clear that the female patients with breast cancer having the CD44 polymorphisms in CD44 exon 2 coding sequence had breast cancer disease at earlier ages and larger tumor burdens when they were diagnosed with breast cancer, differences which were statistically significant ( Fig. 4 ), suggesting that CD44 polymorphisms in the CD44 exon 2 coding region play an important role in breast cancer development.
A number of prediction models such as the Gail Model (Gail et al., 1989) Our statistical analysis showed that the patients having the CD44 polymorphisms in CD44 exon 2 coding sequence had significantly higher probability and higher Assessment of breast cancer risk in patient population. (a) Comparison of breast cancer probability between the patients who did not have CD44 polymorphisms in CD44 exon 2 coding region and those who had CD44 polymorphisms in CD44 exon 2 coding sequence. Y axis was the probability of NOT having breast cancer. (b) Comparison of cumulative risk for breast cancer between the patients having no CD44 polymorphisms and those having CD44 polymorphisms in CD44 exon 2 coding region. The Kaplan-Meier approach was used to generate both probability and cumulative risk curves. The Gehan rank test was used to determine the statistical difference.
cumulative risk for breast cancer (Fig. 5) . Thus, based on the breast cancer probability curve and cumulative risk curve of CD44 polymorphisms, we may establish a prediction model for breast cancer risk.
CD44 is an adhesion molecule of the hyaluronate receptor family. CD44 function depends on its binding to its ligands such as hyaluronan. It has been reported that the function of CD44-hyaluronan binding is responsible for cell-to-cell and cell-to-extracellular matrix interactions (Aruffo, 1996) , apoptosis inhibition (Kaneko et al., 2000) , lymphocyte stimulation (Lesley et al., 1997) , and augmentation of tumor cell motility and metastasis (Thomas and Speight, 2001) . CD44 has two binding domains for hyaluronan, one in the exon 2 region and another in the exon 5 region (Telen et al., 1996) . Therefore, we are interested in understanding gene polymorphisms in CD44 exon 2 and exon 5 in breast cancer. In this study, multiple CD44 polymorphisms in the CD44 exon 2 coding region were identified in patients with breast cancer. However, we cannot rule out that CD44 polymorphisms in other exons may also play a critical role in breast cancer development. Furthermore, analysis of CD44 polymorphisms in a larger sample is necessary to confirm the association between CD44 polymorphisms and breast cancer risk to establish a prediction mode for breast cancer risk assessment.
